Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2, Multicenter, Open-label Study of Carfilzomib, Carboplatin, and Etoposide in Subjects With Previously Untreated Extensive-stage Small-cell Lung Cancer

NCT01987232 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01987232
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01987232 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2, Multicenter, Open-label Study of Carfilzomib, Carboplatin, and Etoposide in Subjects With Previously Untreated Extensive-stage Small-cell Lung Cancer
Lead sponsor
Amgen
Phase
Phase 1/2
Overall status
Completed
Start date
November 5, 2013
Completion date
May 4, 2017
Enrollment
32 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

extensive-stage small-cell lung cancer